TeamDrive
RUS

Company

Team Drive was founded in 2011 as the brainchild of two of Russia’s most successful and prominent business leaders, Leonid Melamed (ex-CEO of Sistema JSFC*, Russia’s largest publically traded holding, and previously CEO of Rosno, Russia’s largest insurer and MTS, Russia’s largest telecommunications operator) and Vladimir Gurdus (ex-CEO of Medsi, Russia’s largest private healthcare provider). 

Having spent two decades successfully conceiving, building, operating and exiting  multi-billion-dollar brands and businesses in Russia and the CIS, Leonid and Vladimir came to the conclusion that not only could Russian assets and businesses be created that were highly competitive in Russia, but highly competitive at global scale, with concomitant returns to equity. In other words, that Russian assets, capital, talent, ideas, companies and brands represent a vast and largely untapped reservoir of investor and customer value potential, both in a Russian market context as well as in a global market context. Team Drive was created specifically to unlock this untapped value potential.

We offer an end-to-end asset management and value augmentation service in Russia with a focus on distressed or underperforming assets going all the way from initial control, creditor/investor alignment, goals/objectives definition, detailed brand and market differentiation strategy to business planning, operational execution and optimal exit, operating to global best practices. 


*Sistema JSFC is the largest publicly-traded diversified holding company in Russia and the CIS. Incorporated in 1993, Sistema is now one of Russia's top ten companies by revenues and is one of the largest investment companies in the world. The group owns a diverse set of public and private companies, which it holds in two distinct portfolios.

Media Center

  • 17 August 2018

    Researchers developed a new class of drugs to reduce cardiovascular risk

    Researchers from Cleveland Clinic (Cleveland, Ohio, USA) have designed a potential new class of drugs that may reduce cardiovascular risk by targeting a specific microbial pathway in the gut.

  • 16 August 2018

    The Pulse of Biopharma M&A

    M&A-driven dealmaking in 2018 across the biopharmaceutical industry is on track to becoming the second highest of the decade. “There’s been a significant increase in private financing, principally driven by Series A financing, which tells us that new company formation has accelerated in the last four to five years,” says Neel Patel, managing director, commercial strategy and planning, at Syneos Health Consulting, and co-author of theNeel Patel 2018 Dealmakers’ Intention Study. 

  • 15 August 2018

    What Issues Are Top of Mind for Smaller Biotech and Emerging Biopharma Companies?

    As a small biotech company proceeds from startup phase through rapid growth of its operations, it will face many critical decisions along the way. Indeed, many of the decisions will be pivotal to determining whether the company will successfully move from a small incubator of ideas to the ability to shepherd a R&D asset through its pipeline to achieving commercial success. This article will provide readers with selected examples of such decisions, plus questions or factors to be considered when making decisions that will have significant impact on the future of their growing firm. 

  • 14 August 2018

    FPI conducts preclinical trials of drug intended to save seriously injured

    Human trials of the drug being developed to save the seriously injured and to extend the “golden hour” – the time regarded as the most critical for saving lives – can begin at least in three years, according to Anatoly Kovtun, Head of the project group of the Foundation for Advanced Research Projects (FPI).

Read more